AP780A - Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist to PPAR-gamma. - Google Patents

Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist to PPAR-gamma. Download PDF

Info

Publication number
AP780A
AP780A APAP/P/1997/000935A AP9700935A AP780A AP 780 A AP780 A AP 780A AP 9700935 A AP9700935 A AP 9700935A AP 780 A AP780 A AP 780A
Authority
AP
ARIPO
Prior art keywords
phenyl
alkyl
optionally substituted
heterocyclic group
methyl
Prior art date
Application number
APAP/P/1997/000935A
Other versions
AP9700935A0 (en
Inventor
Timothy Mark Willson
Robert Antony Mook Jr
Istvan Kaldor
Brad Richard Henke
David Norman Deaton
Jon Loren Collins
Jeffrey Edmond Cobb
Markus Brackeen
Matthew Jude Sharp
John Mark Ocallaghan
Greg Alan Erickson
Grady Evan Boswell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10789571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP780(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AP9700935A0 publication Critical patent/AP9700935A0/en
Application granted granted Critical
Publication of AP780A publication Critical patent/AP780A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C1-6alkyl, C1-3alkoxy, C1-3fluoroalkoxy, nitrile, or -NR7R8 where R7 and R8 are independently hydrogen or C1-3alkyl; (ii) a 5- or 6-membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C1-6alkylene; (v) -MC1-6alkyiene or C1-6alkyleneMC1-6alkylene, wherein M is O, S, or-NR2 wherein R2 represents hydrogen or C1-3 alkyi; (vi) a 5-or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C1-3 alkyl; and (vii) Het-C1-6alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above; Alk represents C1-3alkylene; R1 represents hydroqen or C1-Salkyl; Z is selected from the group consisting of: (viii) -(C1-3alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and (ix) -NR3R4, wherein R3 represents hydrogen or C1-Salkyl, and R4 represents -Y-(C=O)-T-R5, or -Y-(CH(OH))-T-R5.

Description

Chemical Compounds
The present invention relates to certain novel compounds, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit activation, including agonist activity, to peroxisome proliferator-activated receptor gamma (PPAR-gamma) thereby enabling them to modulate the blood glucose levels in mammals.
The treatment of Type II or Non-Insulin Dependent Diabetes Mellitus (NIDDM) remains unsatisfactory despite the widespread use of insulin, sulfonylureas (e.g. chlorpropamide, tolbutamide, tolazamide), and biguanides (e.g, phenformin, metformin) as oral hypoglycaemic agents. Treatment of NIDDM usually begins with a combination of diet and exercise, with progression to oral hypoglycaemics (e.g. sulfonylureas) and in more severe cases, insulin. Unfortunately the available hypoglycaemics suffer from a wide range of undesirable toxic effects which limits their usefulness in treatment of NIDDM. There is thus a clear need for the development of novel hypoglycaemic agents which may be less toxic or which suceed where others are ineffective.
In the last decade a class of compounds known as thiazolidinediones (e.g. U.S. Pat Nos. 5,089,514, 4,342,771, 4,367,234, 4,340,605, 5,306,726) have emerged as effective antidiabetic agents that enhance the insulin sensitivity of target tissues (skeletal muscle, liver, adipose) in animal models of NIDDM and also reduce lipid and insulin levels in these animal models. Recently, the thiazolidinedione troglitazone was shown to have these same beneficial effects in human patients suffering from impaired glucose tolerance, a metabolic condition that precedes the development of NIDDM, as in patients suffering from NIDDM (J. J. Nolan et. al., N. Eng. J. Med. 1188-1193, 331 (1994)). While the mechanism of action is unclear, thiazolidinediones do not cause increases in insulin secretion or in the number or affinity of insulin receptor binding sites, suggesting that thiazolidinediones amplify post-receptor events in the insulin signaling cascade (J. R. Colca and D. R. Morton, "Antihyperglycemic thiazolidinediones: ciglitazone and its analogs," in New Antidiabetic Drugs, C. J. Bailey and P. R. Flatt, eds., Smith-Gordon, New York, 255-261 (1990)).
Thiazolidinediones also induce the in vitro adipocyte differentiation of preadipocyte cell lines (A. Hiragun, et. al. J. Cell. Physiol. 124-130, 134 (1988); R. F. Kleitzen, et. al., Mol. Pharmacol. 393-398, 41 (1992)). Treatment of pre-adipocyte cell lines with the thiazolidinedione pioglitazone results in increased expression of the adipocyte-spec'flc genes aP2 and adipsin as well as the glucose transporter proteins GLUT-1 and GJJT-4, which suggests that the hypoglycaemic effects of thiazolidinediones seen in vivo may be mediated through adipose tissue.
Recently, an orphan member of the steroid/thyroid/retinoid receptor superfamily of ligand-activated transcription factors termed Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma) has been discovered. PPAR-gamma is one of a subfamily of closely related PPARs encoded by independent genes (C. Dreyer, et. al., Cell 879-887, 68 (1992); A. Schmidt, et. al., Mol. Endocrinol. 1634-1641, 6, (1992); Y. Zhu, et. al., J. Biol. Chem. 26817-26820, 268 (1993); S. A. Kliewer et. al., Proc. Nat. Acad. Sci. USA 7355-7359, 91, (1994)). Three mammalian PPARs have been isolated and termed PPAR-alpha, PPAR-gamma, and NUC-1. These PPARs regulate expression of target genes by binding to DNA sequence elements, termed PPAR response elements (PPRE). To date, PPRE's have been identified in the enhancers of a number of genes encoding proteins that regulate lipid metabolism suggesting that PPARs play a pivotal role in the adipogenic signaling cascade and lipid homeostasis (H. Keller and W. Wahli, Trends Endocrin. Met. 291-296, 4 (1993)). It has now been reported that thiazolidinediones are potent and selective activators of PPAR-gamma and bind directly to the PPAR-gamma receptor (J. M. Lehmann et. al., J. Biol. Chem. 12953-12956, 270 (1995)), providing evidence that PPAR-gamma is a possible target for the therapeutic actions of the thiazolidinediones.
We have now discovered a novel group of compounds which bind to and activate the PPAR-gamma receptor. These compounds also show good blood-glucose lowering activity and are therefore of use in the treatment and/or prophylaxis of hyperglycaemia, dyslipidemia, and are of particular use in the treatment of Type II diabetes.
These compounds are also indicated to be of use for the treatment and/or prophylaxis of other diseases including Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension and cardiovascular disease, especially atherosclerosis. In addition, these compounds are indicated to be useful for the regulation of appetite and food intake in subjects suffering from disorders such as obesity, anorexia bulimia, and anorexia nervosa.
Accordingly, the present invention is directed to compounds having the formula (I):
wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more of the following groups; halogen atoms, C^alkyl, C1.3 alkoxy, C,.3 fluoroalkoxy, nitrile, or -NR7R8 where R7 and R8 are independently hydrogen or C1.3alkyl; (ii) a 5- or 6- membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring
; wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) alkylene;
(v) -MC^alkylene or Ci^alkyleneMC-,^alkylene, wherein M is O, S, or -NR2 wherein R2 represents hydrogen or Ci_3alkyl; (vi) a 5- or 6- membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C-,.3 alkyl; and (vii) Het-C^alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above;
Aik represents Ci.3alkylene; R1 represents hydrogen or alkyl; Z is selected from the group consisting of: (viii) -(C^alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and (ix) -NR3R4, wherein R3 represents hydrogen or CV3 alkyl, and R4 represents -Y-(C=O)-T-R5 , or -Y-(CH(0H))-T-R5, wherein: (a) Y represents a bond, alkylene, C2^ alkenylene, C4.6 cycloalkylene or cycloalkenylene, a heterocyclic group as defined in point (vi) above, or phenyl optionally substituted by one or more alkyl groups and/or one or more halogen atoms; (b) T represents a bond, Cv3 alkyleneoxy, -0- or -N(R6)-, wherein R6 represents hydrogen or CV3 alkyl; (c) R5 represents C145 alkyl, C4_6 cycloalkyl or cycloalkenyl, phenyl (optionally substituted by one or more of the following groups; halogen atoms, Cv3 alkyl, C-|.3 alkoxy groups, Co.3alkyleneNR9R10 (where each R9 and R10 is independently hydrogen, CV3 alkyl, -SO2C1.3alkyl, or -CO2C1.3alkyl, -SO2NHC1.3alkyl), C0.3 alkyleneCO2H, C0.3 alkyleneCO2C1.3alkyl, or OCH2C(O)NH2), a 5- or 6- membered heterocyclic group as defined in point (ii) above, a bicylic fused ring wherein ring D represents a 5- or 6- membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfui md optionally substituted by (=0), which bicyclic ring is attached to T via a ring atom of ring D: or -C^alkyleneMR11 M is 0, S, or -NR2 wherein R12 and R11 are independently hydrogen or Ct.3 alkyl; or a tautomeric form thereof, and/or a pharmaceutically acceptable salt or solvate thereof.
Those skilled in the art will recognize that stereocenters exist in compounds of Formula (I). Accordingly, the present invention includes all possible stereoisomers and geometric isomers of Formula (I) and includes not only racemic compounds but also the optically active isomers as well. When a compound of Formula (I) is desired as a single enantiomer, it may be obtained either by resolution of the final product or by stereospecific synthesis from either isomerically pure starting material or any convenient intermediate. Resolution of the final product, an intermediate or a starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Carbon Compounds by E. L. Eliel (Mcgraw Hill, 1962) and Tables of Resolving Agents by S. H. Wilen. Additionally, in situations where tautomers of the compounds of Formula (I) are possible, the present invention is intended to include all tautomeric forms of the compounds.
It will also be appreciated by those skilled in the art that the compounds of the present invention may also be utilized in the form of a pharmaceutically acceptable salt or solvate thereof. The physiologically acceptable salts of the compounds of Formula (I) include conventional salts formed from pharmaceutically acceptable inorganic or organic acids or bases as well as quaternary ammonium acid addition salts. More specific examples of suitable acid salts include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, perchloric, fumaric, acetic, propionic, succinic, glycolic, formic, lactic, maleic, tartaric, citric, pamoic, malonic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, fumaric, toluenesulfonic,
methanesulfonic, naphthalene-2-sulfonic, benzenesulfonic hydroxynaphthoic, hydroiodic, malic, steroic, tannic and the like. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable salts. More specific examples of suitable basic salts include sodium, lithium, potassium, magnesium, c'uminium, calcium, zinc, N,N1-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine salts. References hereinafter to a compound according to the invention include both compounds of Formula (I) and their pharmaceutically acceptable salts and solvates.
The terms C^alkyl or alkylene and C^alkyl or alkylene as used herein respectively contain 1 to 3 or 1 to 6 carbon atoms and appropriately include straight chained and branched alkyl or alkylene groups, typically methyl, methylene, ethyl and ethylene groups, and straight chained and branched propyl, propylene, butyl and butylene groups. The term C2^alkenyl or alkenylene as used herein contains 2 to 6 carbon atoms and appropriately includes straight chained and branched alkenyl and alkenylene groups, in particular propenylene or the like.
The term C-,.3 alkyleneoxy as used herein denotes -O-C^ alkylene-, wherein CV3 alkylene is substantially as defined above, e.g. -0-CH2- etc.
The terms C4.6 cycloalkyl, C4^ cycloalkylene, C4.6 cycloalkenyl and C4.6 cycloalkenylene include cyclic groups containing 4 to 6 carbon atoms, such as cyclopentane, cyclopentylene, cyclohexane, cyclohexylene, cyclohexene and cyclohexenylene.
The term halogen as used herein includes fluorine, chlorine, bromine and iodine.
The term 5- or 6-membered heterocyclic group as used herein includes 5- or 6-membered unsubstituted heterocycloalkyl groups and substituted or unsubstituted heteroaryl groups, e.g. substituted or unsubstituted imidazolidinyl, piperidyl, piperazinyl pyrrolidinyl, morpholinyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyrazolyl, imidazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyI, triazolyl or tetrazolyl.
By substituted heterocyclic group is meant a 5 or 6 membered heteroaryl group substituted by one or more of the following; halogen atoms, alkyl, Cv3 alkoxy groups, Cq_3 alkylene N R9R10 (where each R9 and R10 is idependently hydrogen, Cv 3 alkyl, -SO2C^.3 alkyl or CO2Ci_3 alkyl, -SO2NHCi_3 alkyl), Cq_3 alkylene CO2H, 0θ.3 alkylene CO2C,.3 alkyl, -OCH2C(O)NH2, -Cv3 fluoroalkyl, -CN or alkyl.
In formula (I) above, in the case where Y represents a bond, the nitrogen atom of -NR3R4 is directly linked to -(C=O) or (CH(OH)) of R4, ie. Z represents -N(R3)-(C=O)-T-R5 or -N(R3)(CH(OH))-T-R5. Similarly, in the case where T represents a bond, (C=O) or (CH(OH)) of R4 is directly linked to R5, ie. Z represents -N(R3)-Y-(C=O)-R5 or -N(R3)-Y-(CH(OH))-R5. It may be the case that both Y and T represent a bond, whereby Z represents -N(R3)-(C=O)-R5 or -N(R3)-(CH(OH))-R5.
Aptly A represents any of phenyl, heteroaryl (e.g. pyridyl) or
wherein fused ring C represents a 5-membered heteroaryl group containing at least one nitrogen heteroatom and optionally a further heteroatom selected from nitrogen and oxygen (e.g. oxazolyl, imidazolyl). Particularly A represents any of phenyl, pyridyl, piperazinyl, or benzoxazolyl, any of which can optionally be substituted by one or more CV3 alkyl, especially phenyl, piperazinyl, or pyridyl. B suitably represents ar.y of C-i.3alkylene (e.g. methylene), -N(CH3)Ci_3alkylene (e.g. -N(CH3)(CH2)2-) or Het-C^ alkylene, wherein Het represents a 5- membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen and sulfur (e.g. pyrrolidinyl, oxazolyl and thiazolyl) and aptly substituted by Cv3alkyl. Particularly B represents -N(CH3)(CH2)2, oxazolyl -C^ alkylene, which oxazolyl is optionally substituted by Ci.3 alkyl, or thiazolyl which is optionally substituted by C-i_3 alkyl.
Appropriately Aik represents methylene.
Appropriately R1 represents hydrogen, methyl or ethyl, especially hydrogen.
Suitably Z may represent -(C^alkylene) phenyl substituted by one or more halogen atoms, such as optionally substituted benzyl. Preferably Z represents -NR3R4 substantially as hereinbefore described. Generally R3 represents hydrogen. As hereinbefore described, R4 represents -Y-(C=O)-T-R5, or -Y-(CH(OH))-T-R5 especially -Y(C=O)-T-R5, and particular groupings represented by R4 include: Y represents phenyl (optionally substituted by one or more halogen atoms, r one or more Ci_3alkyl e.g. methyl groups), T represents a bond or an oxygen atom, and R5 represents C1.3 alkyl or phenyl (optionally substituted by one or more halogen atoms or one or more Cv3 alkyl groups); Y represents a heterocyclic group substantially as hereinbefore described (e.g. thienyl), T represents a bond and R5 represents phenyl (optionally substituted by one or more halogen atoms or one or more CV3 alkyl groups); Y represents C^alkenylene- (e.g. propenylene), T represents a bond and R5 represents phenyl (optionally substituted by one or more halogen atoms); Y represents C4.6cycloalkenylene- (e.g. cyclohexenylene), T represents a bond and R5 represents phenyl; Y represents phenyl, T represents a bond and R5 represents a heterocyclic group substantially as hereinbefore described (e.g. piperidyl); Y represents a bond, T represents a bond and R5 represents a bicyclic ring substantially as hereinbefore described (e.g. D represents a 6-membered heterocyclic ring, in particular pyranyl substituted by (C=0)); Y represents phenyl, T represents a bond and R5 represents C^cycloalkyl (e.g. cyclohexyl); Y represents phenyl, T represents alkyleneoxy (e.g. -O-CH2-) or N(R6)- (e.g. -NH-) and R5 represents phenyl.
Preferably when Z represents NR3R4 R3 represents H and R4 represents Y-(C=O)-T-R5 the said NH and said (C=0) are positioned ortho to each other on Y (which is phenyl), T is a bond or -0-, R5 is alkyl, or phenyl (optionally substituted by one or more: halogen atoms, Cv3 alkyl, C-,.3 alkoxy groups, Co_3alkyleneNR9R10 where each R9 and R10 is independently hydrogen, CV3 alkyl, -SO2C1.3alkyl, or -0020ν 3alkyl, - SO2NHC1.3alkyl, C0.3 alkyleneCO2H, alkyleneCO2C1.3alkyl, or -OCH2C(O)NH2).
Particularly suitably Y represents phenyl, T represents a bond or -0- and R5 represents CV3 alkyl or phenyl e.g. R4 represents
wherein R13 represents phenyl or OCH3.
An appropriate subgroup of compounds according to the present invention can be represented by formula (la)
wherein A and B are substantially as hereinbefore described, and Ar represents phenyl or a 5- or 6- membered heteroaryl group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and salts and solvates thereof.
Suitably in formula (la), A is selected from phenyl, pyridyl and benzoxazoyl. In particular, A in Formula (la) represents phenyl or pyridyl. Furthermore, B in Formula
(la) is suitably selected from -NR^^alkylene substantially as hereinbefore described and Het-C^alkylene optionally substituted by Ci_3alkyl substantially as hereinbefore described. In particular, B in Formula (la) represents -N(CH3)(CH2)2- or oxazolyl-C^alkylene, which oxazolyl is optionally substituted by Ci_3alkyl, e.g. methyl. A particular subgroup of the compounds of formula 1 are compounds of formula (I): wherein; A is selected from the group consisting of: (i) phenyl optionally substituted by one or more halogen atoms; (ii) a 5- or 6- membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring
wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) alkylene; (v) -NR^^alkylene, wherein R2 represents hydrogen or Ομ3 alkyl; (vi) a 5- or 6- membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by Cv3 alkyl; and (vii) Het-C^alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above;
Aik represents C^alkylene; R1 represents hydrogen or Cv3 alkyl; Z is selected from the group consisting of: (viii) -(C^alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and (ix) -NR3R4, wherein R3 represents hydrogen or Ο·,.3 alkyl, and R4 represents -Y-(C=O)-T-R5 , or -Y-(CH(OH))-T-R5, wherein: (a) Y represents a bond, alkylene, C2^ alkenylene, C4.6 cycloalkylene or cycloalkenylene, a heterocyclic group as defined in point (vi) above, or phenyl optionally substituted by one or more Cv3 alkyl groups and/or one or more halogen atoms; (b) T represents a bond, Cv3 alkyleneoxy, -0- or -N(R6)-, wherein R6 represents hydrogen or CV3 alkyl; (c) R5 represents alkyl, C4.6 cycloalkyl or cycloalkenyl, phenyl optionally substituted by one or more halogen atoms or one or more Cv3 alkyl groups, a 5- or 6- membered heterocyclic group as defined in point (ii) above, or a bicylic fused ring
wherein ring D represents a 5- or 6- membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by (=0), which bicyclic ring is attached to T via a ring atom of ring D; or a tautomeric form thereof, and/or a pharmaceutically acceptable salt or solvate thereof.
Particular compounds according to the present invention include:
3-(4-Benzyloxy-phenyl)-2(S)-(1-methyl-3-oxo-3-phenyl-propenylamino)-propionic acid dicyclohexylamine salt 3-(4-Benzyloxy-phenyl)-2(S)-(1-methyl-3-oxo-3-phenyl-propenylamino)-propionic acid methyl ester 2(S)-(2-Benzoyl-cyclohex-1-enylamino)-3-(4-benzyloxy-phenyl)-propionic acid dicyclohexylamine salt 2- (2-benzoylphenylamino)-3-(4-benzyloxyphenyl) propanoic acid 3- (4-Benzyloxy-phenyl)-2-(2-benzyloxy-phenylamino)-propionic acid methyl ester 3-(4-Benzyloxy-phenyl)-2-(phenylcarbamoyl-phenylamino)-propionic acid methyl ester 3-(4-Benzyloxy-phenyl)-2-[2-(piperidine-1-carbonyl)-phenylamino]-propionic acid methyl ester 2-(3-Benzoyl-thiophen-2-yl-amino)-3-(4-benzyloxy-phenyl)-propionic acid 2- (2-Benzoyl-thiophen-3-yl-amino)-3-(4-benzyloxy-phenyl)-propionic acid 3- (4-Benzyloxy-phenyl)-2(S)-[(4-oxo-4H-chromene-3-carbonyl)-amino]-propionic acid methyl ester. 2-(2-Benzoyl-phenylamino)-3-{4-[2-(methyl-pyridin-2-yl-amino)-ethoxy]-phenyl}-propionic acid 2(S)-(2-benzoyl-phenylamino)-3-{4-[2-(methyl-pyridin-2-yl-amino)-ethoxy]-phenyl}-propionic acid 2-(2-Benzoyl-phenylamino)-3-{4-[2-(methyl-pyridin-2-yl-amino)-ethoxy]-phenyl}-propionic acid ethyl ester 2- (1-Methyl-3-oxo-3-phenyl-propenylamino)-3{4-[2-(methyl-pyridin-2-yl-amino)-ethoxy]-phenyl}-propionic acid dicyclohexylamine salt 3- {4-[2-(benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-(2-benzoyl-phenylamino)-propionic acid 3-{4-[2-(benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-(2-benzoyl-phenylamino)-propionic acid 3-{4-[2-(Benzoxazol-2yl-methyl-amino)-ethoxy]-phenyl}-2(S)-(1-methyl-3-oxo-3-phenyl-propenylamino)-propionic acid dicyclohexylamine salt 3-{4-[2-(Benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2(S)-[3-(3-iodo-phenyl)-1-methyl-3-oxo-propenylamino]-propionic acid dicyclohexylamine salt 3-{4-[2-(benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-(2-benzoyl-4-methyl-phenylamino)-propionic acid 3-{4-[2-(benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-(2-benzoyl-4-chloro-phenylamino)-propionic acid 3-[4-(1-Benzoxazol-2-yl-pyrrolidin-3-yloxy)-phenyl]-2-(2-benzoyl-phenylamino)-propionic acid 3-[4-(1-benzoxazol-2-yl)-pyrrolidin-2R-yl-methoxy)-phenyl]-2-(2-benzoyl-pheny(amino)-propionic acid 3-[4-(1-benzoxazol-2-yl)-pyrrolidin-2S-yl-methoxy)-phenyl]-2-(2-benzoyl-phenylamino)-propionic acid 3-{4-[2-(Benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyI}-2-(2-cyclohexanecarbonyl-phenyiamino)-propionic acid 3-{4-[2-Benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-(2-benzoyl-thiophen-3-ylamino)-propionic acid. 3-{4-[2-(Benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-benzyl-propionic acid trifluoroacetate. 3-{4-[2-(Benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2-(2-bromo-benzyl)-propionic acid trifluoroacetate. 3-{4-[2-(Benzoxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-2(S)-[(4-oxo-4H-chromene-3-carbonyl)-amino]-propionic acid. 2(S)-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid 2- (2-Benzoyl-phenylamino)-3-{4-[2-(4-chlorophenyl)-thiazol-4ylmethoxy]-phenyl}-propionic acid 3- [4-(2-Benzoimidazol-1-yl-ethoxy)-phenyl]-2-(2-benzoyl-phenylamino)-propionic acid 2(S)-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-(4-methoxy)-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid 2(S)-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-(4-fluoro)-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid 2(S)-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-(5-methyl-thien-2-yl)-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid 2(S)-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-1-phenyl-1H-pyrazol-3-yl)-ethoxy]-phenylj-propionic acid

Claims (1)

  1. Original document published without claims.
APAP/P/1997/000935A 1996-02-28 1997-02-27 Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist to PPAR-gamma. AP780A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9604242.9A GB9604242D0 (en) 1996-02-28 1996-02-28 Chemical compounds

Publications (2)

Publication Number Publication Date
AP9700935A0 AP9700935A0 (en) 1997-04-30
AP780A true AP780A (en) 1999-11-22

Family

ID=10789571

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/000935A AP780A (en) 1996-02-28 1997-02-27 Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist to PPAR-gamma.

Country Status (41)

Country Link
US (1) US6294580B1 (en)
EP (1) EP0888317B1 (en)
JP (1) JP3255930B2 (en)
KR (1) KR100462730B1 (en)
CN (1) CN1093124C (en)
AP (1) AP780A (en)
AR (1) AR011502A1 (en)
AT (1) ATE205485T1 (en)
AU (1) AU717699B2 (en)
BG (1) BG102792A (en)
BR (1) BR9707786B1 (en)
CA (1) CA2247443C (en)
CY (1) CY2319B1 (en)
CZ (1) CZ295383B6 (en)
DE (1) DE69706658T2 (en)
DK (1) DK0888317T3 (en)
EA (1) EA001403B1 (en)
EE (1) EE9800288A (en)
ES (1) ES2163125T3 (en)
GB (1) GB9604242D0 (en)
GE (1) GEP20012580B (en)
HK (1) HK1015369A1 (en)
HR (1) HRP970110B1 (en)
HU (1) HUP0004845A3 (en)
ID (1) ID15985A (en)
IL (1) IL125796A (en)
IS (1) IS1869B (en)
MY (1) MY119425A (en)
NO (1) NO311516B1 (en)
NZ (1) NZ331381A (en)
OA (1) OA10843A (en)
PE (1) PE43098A1 (en)
PL (1) PL191118B1 (en)
PT (1) PT888317E (en)
RS (1) RS49586B (en)
SI (1) SI0888317T1 (en)
SK (1) SK282753B6 (en)
TR (1) TR199801707T2 (en)
UA (1) UA58502C2 (en)
WO (1) WO1997031907A1 (en)
ZA (1) ZA971645B (en)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0925063A4 (en) * 1996-07-01 2000-12-27 Lilly Co Eli Hypoglycemic and hypolipidemic compounds
CA2263721A1 (en) 1996-08-19 1998-02-26 Satoshi Ohrui Propionic acid derivatives and applications thereof
DE69838789T2 (en) 1997-03-12 2008-10-30 Suzanne Cambridge de la Monte METHOD FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE
ES2200248T3 (en) * 1997-09-19 2004-03-01 Ssp Co., Ltd. DERIVATIVES OF ACUDI FENILPROPIONICO REPLACED IN ALFA AND MEDICINAL PRODUCT CONTAINING THEM.
IL135177A0 (en) * 1997-10-02 2001-05-20 Sankyo Co Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
US6444816B1 (en) * 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
DE69939864D1 (en) 1998-01-29 2008-12-18 Amgen Inc PPAR-GAMMA MODULATORS
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
ES2226413T3 (en) 1998-02-26 2005-03-16 Celltech Therapeutics Limited PHENYLALANINE DERIVATIVES AS INTEGRIN ALFA-4 INHIBITORS.
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
SK16412000A3 (en) * 1998-05-11 2001-08-06 Takeda Chemical Industries, Ltd. OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC ANDì (54) HYPOLIPIDEMIC ACTIVITY
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
SE9801990D0 (en) 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (en) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (en) 1998-06-04 2004-12-20 Astra Ab NOVEL 3-ARYL PROPIONIC ACID DERIVATIVES AND THE LIKE
ATE274510T1 (en) * 1998-06-19 2004-09-15 Chiron Corp GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9817118D0 (en) 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9821061D0 (en) * 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
US6589969B1 (en) * 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
ATE476978T1 (en) * 1998-12-17 2010-08-15 Mindset Biopharmaceuticals Usa IMPROVE MENTAL ABILITIES BY INCREASE THE BRAIN'S INSULIN SENSITIVITY
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
KR20020060067A (en) 1999-04-06 2002-07-16 가와무라 요시부미 α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES
US6528507B1 (en) 1999-04-16 2003-03-04 Dr. Reddy's Laboratories Limited Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
EP1171430A1 (en) * 1999-04-16 2002-01-16 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
WO2000063193A1 (en) * 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
CA2370742A1 (en) * 1999-04-19 2000-10-26 Coelacanth Corporation Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
WO2000063153A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
JP2002542237A (en) * 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ New compounds, their production and use
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
US6369055B1 (en) 1999-04-20 2002-04-09 Novo Nordisk A/S Compounds, their preparation and use
AU3958100A (en) * 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
US7414128B2 (en) 1999-04-20 2008-08-19 Dr. Reddy's Laboratories, Limited Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
RU2278114C2 (en) * 1999-04-28 2006-06-20 Др.Редди З Лабораториз Лимитед Substituted bicyclic heterocyclic compounds, method for their preparing (variants) and using as agents against obesity and hyperholesterolemia
PL351470A1 (en) * 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
JP4618845B2 (en) * 1999-06-09 2011-01-26 杏林製薬株式会社 Substituted phenylpropionic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha agonists
GB9913782D0 (en) * 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
IL147308A0 (en) * 1999-06-30 2002-08-14 Tularik Inc Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6417212B1 (en) * 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
CA2385083C (en) 1999-09-17 2007-06-05 Kyorin Pharmaceutical Co., Ltd. O-anisamide derivatives
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
EP1939188A1 (en) * 1999-09-22 2008-07-02 Bristol-Myers Squibb Company Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
SE9904415D0 (en) * 1999-12-03 1999-12-03 Astra Ab New process
AU782631C (en) * 1999-12-03 2006-08-17 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP4316787B2 (en) * 2000-01-11 2009-08-19 壽製薬株式会社 An ether or amide derivative, a process for producing the same, and a therapeutic agent for diabetes containing the same,
JP2001261674A (en) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc Benzothiophene derivative and intranuclear receptor agonist
DE60130910T2 (en) 2000-04-17 2008-07-10 Ucb Pharma, S.A. ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
FR2808798A1 (en) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
EP1301488A1 (en) 2000-07-07 2003-04-16 Celltech R&D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
WO2002010136A1 (en) 2000-08-02 2002-02-07 Celltech R & D Limited 3-substituted isoquinolin-1-yl derivatives
AU2001278738A1 (en) * 2000-08-16 2002-02-25 Sankyo Company Limited Medicinal compositions for preventing and treating cancer
JP2004506722A (en) 2000-08-23 2004-03-04 イーライ・リリー・アンド・カンパニー Methods of modulating peroxisome proliferator-activated receptors
US6982278B2 (en) 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
IL154110A0 (en) 2000-08-23 2003-07-31 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
NZ526687A (en) * 2000-12-25 2004-08-27 Ono Pharmaceutical Co Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient
EP1695716A2 (en) 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
DE60237594D1 (en) * 2001-04-25 2010-10-21 Takeda Pharmaceutical USE OF THE ABC EXPRESSION PROMOTOR PIOGLITAZONE FOR THE TREATMENT OF ARTERIOSCLEROSIS OBLITERANS
AU2002342244B2 (en) * 2001-05-15 2005-06-16 F. Hoffmann-La Roche Ag Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
BR0209711A (en) 2001-05-29 2004-11-03 Kyoto Pharma Ind Heterocyclic compound and its medicinal use
CZ20033415A3 (en) 2001-05-29 2004-06-16 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal utilization thereof
DE10127126A1 (en) * 2001-06-05 2002-12-19 Forschungszentrum Juelich Gmbh New protected O-(2-substituted ethyl)-L-tyrosine derivatives, useful as intermediates for the positron emission tomography contrast agent O-(2-(18F)-fluoroethyl)-L-tyrosine
SK14912003A3 (en) * 2001-06-07 2004-09-08 Eli Lilly And Company Receptor modulators activated by peroxizonal proliferators (PPAR)
PL367077A1 (en) 2001-06-07 2005-02-21 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
EP1414785A1 (en) * 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
JP2005503377A (en) * 2001-07-30 2005-02-03 ノボ　ノルディスク　アクティーゼルスカブ Novel vinyl N- (2-benzoylphenyl) -L-tyrosine derivatives and their use in antidiabetic agents, etc.
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
TW200300681A (en) 2001-11-12 2003-06-16 Ono Pharmaceutical Co Carboxylic acid derivative compound and medicament containing same as active ingredient
BR0214437A (en) 2001-11-30 2004-10-13 Lilly Co Eli Compound, pharmaceutical composition, methods of modulating a peroxisome proliferator-activated receptor, treating and preventing diabetes mellitus, and treating syndrome x, and cardiovascular disease in a mammal, and, use of a compound
TW200300677A (en) * 2001-12-11 2003-06-16 Sankyo Co A pharmaceutical composition
ATE319449T1 (en) * 2001-12-21 2006-03-15 Smithkline Beecham Corp DOSAGE SCHEME FOR PPAR-GAMMA ACTIVATORS
AU2002366980A1 (en) 2002-01-17 2003-07-30 Toaeiyo Ltd. Halogenobenzyl aminopropionic acid derivatives
WO2003062427A1 (en) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Method of screening drug for improving insulin resistance
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
JP2004277397A (en) * 2002-05-24 2004-10-07 Takeda Chem Ind Ltd 1, 2-azole derivative
WO2003099793A1 (en) * 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
GB0214149D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
JP4541883B2 (en) * 2002-07-09 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー Substituted heterocyclic derivatives and methods useful as antidiabetic and antiobesity agents
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
US6653334B1 (en) 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
MXPA05008581A (en) 2003-02-14 2005-11-04 Lilly Co Eli Sulfonamide derivatives as ppar modulators.
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US20060142356A1 (en) * 2003-02-17 2006-06-29 Davis Adrian F Novel therapeutic method and compositions for topical administration
US20050059708A1 (en) * 2003-05-13 2005-03-17 Karel Pospisilik Processes for making thiazolidinedione derivatives and compounds thereof
RU2344135C2 (en) 2003-07-02 2009-01-20 Ф.Хоффманн-Ля Рош Аг Thiazole-substituted indolyl-derivatives and application theirof as ppar modulators
US20070293423A1 (en) * 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
CA2532026C (en) * 2003-08-20 2012-04-17 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
TW200526588A (en) * 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
EP1688138A4 (en) 2003-11-26 2008-01-16 Takeda Pharmaceutical Receptor function regulating agent
BRPI0417401A (en) * 2003-12-15 2007-05-08 Lilly Co Eli compound, pharmaceutical composition, methods for modulating a peroxisome proliferator-activated receptor, for treating disease or condition, for lowering blood glucose in a mammal, for treating diabetes mellitus in a mammal, for treating cardiovascular disease in a mammal, for treating syndrome x in a mammal, and, compost use
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
AU2005219536A1 (en) * 2004-03-09 2005-09-15 F. Hoffmann-La Roche Ag Pyrazolyl indolyl derivatives as PPAR activators
DK1734970T3 (en) 2004-03-12 2015-02-16 Intercept Pharmaceuticals Inc Treatment of fibrosis using FXR ligands
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ATE405544T1 (en) 2004-07-30 2008-09-15 Salvat Lab Sa TYROSINE DERIVATIVES AS PPAR-GAMMA MODULATORS
JPWO2006016637A1 (en) * 2004-08-11 2008-05-01 杏林製薬株式会社 New cyclic aminobenzoic acid derivatives
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
PL371841A1 (en) 2004-12-20 2006-06-26 ADAMED Sp.z o.o. New derivatives of 3-phenylpropionic acid
PL372332A1 (en) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. New compounds, derivatives of 3-phenylpropionic acid
PL372356A1 (en) 2005-01-20 2006-07-24 ADAMED Sp.z o.o. New compounds, derivatives of 3-phenylpropionic acid
WO2006082495A1 (en) * 2005-02-02 2006-08-10 Ranbaxy Laboratories Limited Peroxisome proliferator activated receptor modulators
ITMI20050912A1 (en) 2005-05-19 2006-11-20 Erregierre Spa PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
AU2006282403B2 (en) 2005-08-26 2011-07-07 Institute Of Medicinal Molecular Design, Inc. Derivative having PPAR agonistic activity
US8653115B2 (en) * 2006-06-13 2014-02-18 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
EP2213289A1 (en) 2006-09-07 2010-08-04 Nycomed GmbH Combination treatment for diabetes mellitus
EP2061442B1 (en) 2006-09-08 2016-08-31 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
MX2009007728A (en) 2007-01-19 2009-12-15 Intercept Pharmaceuticals Inc 23-substituted bile acids as tgr5 modulators and methods of use thereof.
JP2008239616A (en) * 2007-02-28 2008-10-09 Iyaku Bunshi Sekkei Kenkyusho:Kk Hdl (high density lipoprotein) enhancer
WO2008117982A1 (en) * 2007-03-28 2008-10-02 Crystal Genomics, Inc. Heterocyclic carboxylic acid derivatives and pharmaceutical composition for inhibiting lipid accumulation containing same
AU2010224037B2 (en) 2009-03-11 2015-02-05 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
KR101622403B1 (en) 2007-04-11 2016-05-31 오메로스 코포레이션 Compositions and methods for prophylaxis and treatment of addictions
US20100274022A1 (en) * 2007-04-26 2010-10-28 Pharmafrontier Co., Ltd. G protein-coupled receptor inhibitor and pharmaceutical product
CA2963857A1 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
EA020310B1 (en) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Tgr5 modulators and use thereof
US8114862B2 (en) 2008-11-19 2012-02-14 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
JP6153606B2 (en) * 2012-06-19 2017-06-28 ヘルムート シーカーネーダー Bendamustine derivatives and related compounds, and their medical use in cancer treatment
CA3028207A1 (en) 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
JP6378752B2 (en) * 2013-05-17 2018-08-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
US9987255B2 (en) 2014-12-19 2018-06-05 Merck Sharp & Dohme Corp. 5,5-bicyclic oxazole orexin receptor antagonists
CN104744282A (en) * 2015-02-17 2015-07-01 南通恒盛精细化工有限公司 Preparation process of insulin sensitizer
WO2019224393A1 (en) * 2018-05-25 2019-11-28 University Of Copenhagen Fenofibrate for reducing hypoglycemia in type 1 diabetes/lada

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4342771A (en) 1981-01-02 1982-08-03 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4367234A (en) 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
RU1473300C (en) 1987-06-01 1995-02-09 Научно-производственное объединение "Витамины" Method of synthesis of 4-benzoylamino-3-oxotetrahydrothiophene
US5220023A (en) 1989-07-18 1993-06-15 Janssen Pharmaceutica N.V. Glycine derivatives
DE3941438A1 (en) 1989-12-15 1991-06-20 Hoechst Ag NEW 2-SUBSTITUTED 4- (3-ALKYL-5-TERT.-BUTYL-4-HYDROXY-PHENYL) -THIAZOLE, PROCESS FOR THEIR MANUFACTURE, THE MEDICAMENT CONTAINING THEIR AND ITS USE
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
AU3959193A (en) 1992-04-10 1993-11-18 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type II-diabetes
NZ253742A (en) 1992-07-03 1997-06-24 Smithkline Beecham Plc Heterocyclylaminoalkoxy substituted phenyl derivatives and pharmaceutical compositions
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
GB9311661D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9311644D0 (en) 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
SE9302332D0 (en) 1993-07-06 1993-07-06 Ab Astra NEW COMPOUNDS
GB9315148D0 (en) 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
JPH08325264A (en) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd New 2-aromatic ring-substituted-3-phenylpropionic acid or acrylic acid derivative
JPH08325263A (en) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd New 2-amino-3-phenylpropionic acid derivative
JPH08325564A (en) 1995-06-05 1996-12-10 Nec Corp Organic thin film el device
EP0925063A4 (en) * 1996-07-01 2000-12-27 Lilly Co Eli Hypoglycemic and hypolipidemic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NONE *

Also Published As

Publication number Publication date
DE69706658D1 (en) 2001-10-18
EP0888317B1 (en) 2001-09-12
CZ295383B6 (en) 2005-07-13
ID15985A (en) 1997-08-21
HUP0004845A2 (en) 2001-05-28
EA001403B1 (en) 2001-02-26
SI0888317T1 (en) 2002-04-30
DK0888317T3 (en) 2002-01-21
BG102792A (en) 1999-08-31
RS49586B (en) 2007-04-10
US6294580B1 (en) 2001-09-25
GB9604242D0 (en) 1996-05-01
BR9707786B1 (en) 2009-12-01
SK282753B6 (en) 2002-12-03
CA2247443C (en) 2009-01-27
IL125796A0 (en) 1999-04-11
HK1015369A1 (en) 1999-10-15
CN1218460A (en) 1999-06-02
YU36998A (en) 1999-09-27
JP2000507216A (en) 2000-06-13
AP9700935A0 (en) 1997-04-30
IS1869B (en) 2003-05-09
NO311516B1 (en) 2001-12-03
PT888317E (en) 2002-03-28
NO983940L (en) 1998-10-27
NZ331381A (en) 2000-06-23
ES2163125T3 (en) 2002-01-16
SK116398A3 (en) 1999-04-13
KR19990087321A (en) 1999-12-27
DE69706658T2 (en) 2002-06-20
BR9707786A (en) 1999-07-27
IL125796A (en) 2001-06-14
IS4822A (en) 1998-08-12
ZA971645B (en) 1997-12-10
HUP0004845A3 (en) 2001-07-30
OA10843A (en) 2001-08-14
CA2247443A1 (en) 1997-09-04
AU717699B2 (en) 2000-03-30
UA58502C2 (en) 2003-08-15
CZ275098A3 (en) 1999-01-13
EE9800288A (en) 1999-02-15
EP0888317A1 (en) 1999-01-07
NO983940D0 (en) 1998-08-27
PL328871A1 (en) 1999-03-01
CN1093124C (en) 2002-10-23
EA199800664A1 (en) 1999-04-29
AU2093597A (en) 1997-09-16
AR011502A1 (en) 2000-08-30
JP3255930B2 (en) 2002-02-12
ATE205485T1 (en) 2001-09-15
PL191118B1 (en) 2006-03-31
GEP20012580B (en) 2001-11-26
HRP970110A2 (en) 1998-04-30
CY2319B1 (en) 2003-11-14
HRP970110B1 (en) 2003-06-30
KR100462730B1 (en) 2005-02-28
WO1997031907A1 (en) 1997-09-04
PE43098A1 (en) 1998-08-30
MY119425A (en) 2005-05-31
TR199801707T2 (en) 1998-12-21

Similar Documents

Publication Publication Date Title
AP780A (en) Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist to PPAR-gamma.
DE60216094T2 (en) MODULATORS OF PEROXISOM PROLIFERATOR ACTIVATED RECEPTORS (PPAR)
KR100634195B1 (en) Dibenzylamine compound and medicinal use thereof
CZ216398A3 (en) Compound exhibiting ppar-alpha and ppar-gamma agonists activity, such agonist and its use, pharmaceutical composition containing thereof and detection method
CN101007804B (en) 1,3-benzodioxole-2,2-dicarboxylic acid derivatives and their preparation method and medicinal uses
MXPA06013581A (en) Substituted triazoles as modulators of ppar and methods of their preparation.
WO2009012650A1 (en) Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof
US4968707A (en) Oxazolidin-2-one derivatives as hypoglycemic agents
RU2303593C2 (en) Chiral derivatives of oxazolarylpropionic acid and their using as agonists or receptor activated by peroxisome proliferator (ppar agonists)
JP2001261612A (en) Catecholpropionic acid derivative and nuclear receptor agonist containing the same as active ingredient
JP3630676B2 (en) Dibenzylamine compound and pharmaceutical use thereof
CA2518986A1 (en) Imino ether derivative compounds and drugs containing the compounds as the active ingredient
JP4530668B2 (en) Indanacetic acid derivatives and their use as drugs
JPWO2002044130A1 (en) Substituted carboxylic acid derivatives
JP4290648B2 (en) Oxazole derivatives and their use as insulin sensitizers
US7781468B2 (en) Tyrosine derivatives substituted by N-arylacryloyl as agonists of hPPAR alpha and/or hPPAR gamma
US20040072690A1 (en) Novel propionic acid derivatives
US7544687B2 (en) Substituted α-piperazinyl phenylpropionic acid derivatives as hPPAR α and/or hPPAR γ agonists
US20070167628A1 (en) Thiazole-2-carboxamide derivatives for use as hippar agonists in the treatment of i.a. dyslipidemia
EP1484316A1 (en) Novel propionic acid derivative
MXPA06006829A (en) Selective peroxisome proliferator activated receptor modulators.
WO2007085202A1 (en) Oxamic acid derivatives,preparation methods and medical uses thereof
JP2004026679A (en) Dihydronaphthalene derivative
JP2004123721A (en) Dihydronaphthalene derivative compound and pharmaceutical agent containing the compound as effective ingredient